02 December 2021
Dear Supporters & Friends,
Thank you for your loyalty and support in 2021, a year which has seen PCFA significantly grow its reach and strengthen its impact to improve outcomes for Australian men and families with prostate cancer.
Against the odds of a global pandemic, we have expanded our Prostate Cancer Specialist Nursing Service to nearly 100 nurses around Australia, an achievement delivered in parallel with the establishment of a new Telenursing Service and plans to launch Australia’s first prostate cancer counselling service in 2022.
Our advocacy has also gone from strength to strength, with successful outcomes on recommendations and listings from both the Medical Services Advisory Committee and the Pharmaceutical Benefits Advisory Committee, including the first listing of a new medicine for prostate cancer in seven years with Nubeqa.
In the area of research, we have committed $1.6m over four years to the EVOLUTION Phase II Clinical Trial under an ongoing partnership with ANZUP, in addition to funding two new rounds of our Priority Research Impact Awards Schemes, for Young Investigators and Early and Mid-Career Researchers.
To further position PCFA for growth, I am delighted to announce that from Friday December 3, Professor Jeff Dunn will take on a new role as Chief of Mission and Head of Research, supported by the promotion of our Chief Operating Officer Anne Savage to the role of Chief Executive Officer.
This step forward will see Jeff increase his focus on local and international research, while Anne continues to drive our advocacy and engagement with the Australian community.
We look forward to collaborating with you in 2022, working together to transform care and improve prostate cancer survivorship.
Adjunct Associate Professor Stephen William Callister
National Chairman | Prostate Cancer Foundation of Australia